Search Within

Samuel Aaron Funt

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (29)
  2. Journal Article (22)
  3. Editorial (1)
Groups
  1. Department of Medicine (52)
  2. Epidemiology and Biostatistics (52)
  3. Genitourinary Oncology Service (52)
  4. Solid Tumor Oncology Division (52)
  5. Weinberg Fellows (52)
  6. Biostatistics Service (47)

More Groups

People
  1. Dean Bajorin (48)
  2. Jonathan Rosenberg (36)
  3. Gopakumar Iyer (34)
  4. Hikmat Al-Ahmadie (28)
  5. Irina Ostrovnaya (27)
  6. Min Yuen Teo (27)

More People

Years
  1. 2025 (1)
  2. 2024 (8)
  3. 2023 (3)
  4. 2022 (7)
  5. 2021 (11)
  6. 2020 (7)

More Years

Publications
  1. Journal of Clinical Oncology (33)
  2. Annals of Oncology (2)
  3. European Urology (2)
  4. JCO Precision Oncology (2)
  5. Annals of Surgery (1)
  6. Annals of Thoracic Surgery (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (35)
  2. Elsevier Science, Inc. (3)
  3. Nature Publishing Group (3)
  4. Oxford University Press (3)
  5. Lippincott Williams & Wilkins (2)
  6. Wiley Blackwell (2)

More Publishers

Results (52)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors
    Journal Article

    Matulewicz, R. S.; Baky, F.; Liso, N.; Williams, B. M.; Porwal, S.; Assel, M.; Carver, B. S.; Bajorin, D. F.; Motzer, R. J.; Bosl, G. J.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer
    Meeting Abstract

    Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes
    Meeting Abstract

    Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results
    Meeting Abstract

    Sternschuss, M.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Goh, A. C.; Cha, E. K.; Donat, S. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Paclitaxel, ifosfamide, and cisplatin as initial salvage chemotherapy for germ cell tumors: Long-term follow-up and outcomes for favorable- and unfavorable-risk disease
    Journal Article

    Gleeson, J. P.; Knezevic, A.; Bromberg, M.; Patil, S.; Sheinfeld, J.; Carver, B. S.; Bains, M.; Jones, D. R.; Bajorin, D. F.; Bosl, G. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Bajorin, D. F.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Correlation of peripheral blood monocytic myeloid-derived suppressor cells (M-MDSC) and T-cell receptor (TCR) dynamics with clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with nivolumab (NIVO)
    Meeting Abstract

    Gupta, A.; Whiting, K.; Keegan, N. M.; Schmalz, J.; Al-Ahmadie, H. A.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Iyer, G.; Rosenberg, J. E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Natural history and genomic landscape of chemotherapy-resistant muscle-invasive bladder cancer
    Journal Article

    Lenis, A. T.; Whiting, K.; Ravichandran, V.; Tallman, J. E.; Alam, S. M.; Chu, C. E.; De Jesus Escano, M.; Bochner, E.; Katims, A.; Reisz, P. A.; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma
    Journal Article

    Vanguri, R. S.; Smithy, J. W.; Li, Y.; Zhuang, M.; Maher, C. A.; Aleynick, N.; Peng, X.; Al-Ahmadie, H.; Funt, S. A.; Rosenberg, J. E.; more...
    Journal of Pathology (2023)

    Fulltext@MSK | Save